Published in Cell Death Dis on October 15, 2015
Inhibition of deubiquitinases primes glioblastoma cells to apoptosis in vitro and in vivo. Oncotarget (2016) 0.82
Patient-derived glioblastoma stem cells respond differentially to targeted therapies. Oncotarget (2016) 0.75
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature (2006) 27.91
c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev (2006) 6.19
Notch signaling is a direct determinant of keratinocyte growth arrest and entry into differentiation. EMBO J (2001) 5.29
Direct inhibition of the NOTCH transcription factor complex. Nature (2009) 4.82
The role of Notch in tumorigenesis: oncogene or tumour suppressor? Nat Rev Cancer (2003) 4.75
Suppressor of hairless directly activates transcription of enhancer of split complex genes in response to Notch receptor activity. Genes Dev (1995) 4.47
NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells (2010) 3.42
Notch promotes radioresistance of glioma stem cells. Stem Cells (2010) 3.07
Delta-1 activation of notch-1 signaling results in HES-1 transactivation. Mol Cell Biol (1998) 2.75
Induction of cyclin D1 transcription and CDK2 activity by Notch(ic): implication for cell cycle disruption in transformation by Notch(ic). Mol Cell Biol (2001) 2.74
New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene (2010) 2.56
Death receptor signaling. J Cell Sci (2005) 2.21
Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. J Clin Oncol (2012) 2.08
Targeting notch signaling pathway in cancer: clinical development advances and challenges. Pharmacol Ther (2013) 1.96
Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Clin Cancer Res (2007) 1.91
Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res (2000) 1.81
Nature's TRAIL--on a path to cancer immunotherapy. Immunity (2003) 1.77
Notch signaling at a glance. J Cell Sci (2013) 1.76
Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins. Oncogene (2008) 1.67
Chemoresistance of glioblastoma cancer stem cells--much more complex than expected. Mol Cancer (2011) 1.64
c-Jun transactivates the promoter of the human p21(WAF1/Cip1) gene by acting as a superactivator of the ubiquitous transcription factor Sp1. J Biol Chem (1999) 1.58
mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells. Mol Cell Biol (2005) 1.56
High-throughput detection and multiplex identification of cell contaminations. Nucleic Acids Res (2009) 1.49
TRAIL and cancer therapy. Cancer Lett (2008) 1.38
A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. Ann Oncol (2012) 1.34
Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity. Biochem Biophys Res Commun (1999) 1.33
Bile acids up-regulate death receptor 5/TRAIL-receptor 2 expression via a c-Jun N-terminal kinase-dependent pathway involving Sp1. J Biol Chem (2003) 1.32
Phosphorylation by c-Jun NH2-terminal kinase 1 regulates the stability of transcription factor Sp1 during mitosis. Mol Biol Cell (2008) 1.31
A first-in-human study of conatumumab in adult patients with advanced solid tumors. Clin Cancer Res (2010) 1.26
Sumoylation of specificity protein 1 augments its degradation by changing the localization and increasing the specificity protein 1 proteolytic process. J Mol Biol (2008) 1.26
Counting colonies of clonogenic assays by using densitometric software. Radiat Oncol (2007) 1.21
Analysis of FasL and TRAIL induced apoptosis pathways in glioma cells. Oncogene (2001) 1.15
Mitochondrial apoptosis: killing cancer using the enemy within. Br J Cancer (2015) 1.13
Notch-1 signaling facilitates survivin expression in human non-small cell lung cancer cells. Cancer Biol Ther (2011) 1.12
Translating TRAIL-receptor targeting agents to the clinic. Cancer Lett (2012) 1.10
DR5-mediated DISC controls caspase-8 cleavage and initiation of apoptosis in human glioblastomas. J Cell Mol Med (2009) 1.09
Transcriptional regulation of EGR-1 by the interleukin-1-JNK-MKK7-c-Jun pathway. J Biol Chem (2008) 1.08
Sodium butyrate sensitizes TRAIL-mediated apoptosis by induction of transcription from the DR5 gene promoter through Sp1 sites in colon cancer cells. Carcinogenesis (2004) 1.08
Notch interferes with the scaffold function of JNK-interacting protein 1 to inhibit the JNK signaling pathway. Proc Natl Acad Sci U S A (2005) 1.08
Induction of cPLA2 in lung epithelial cells and non-small cell lung cancer is mediated by Sp1 and c-Jun. J Biol Chem (2001) 1.07
p53-independent upregulation of KILLER/DR5 TRAIL receptor expression by glucocorticoids and interferon-gamma. Exp Cell Res (2001) 1.06
Promoter structure and transcription initiation sites of the human death receptor 5/TRAIL-R2 gene. FEBS Lett (2001) 1.06
Overview of cellular immunotherapy for patients with glioblastoma. Clin Dev Immunol (2010) 1.05
Molecular mechanisms of death-receptor-mediated apoptosis. Chembiochem (2001) 1.05
Arsenic trioxide sensitizes human glioma cells, but not normal astrocytes, to TRAIL-induced apoptosis via CCAAT/enhancer-binding protein homologous protein-dependent DR5 up-regulation. Cancer Res (2008) 1.04
Costimulatory protein 4IgB7H3 drives the malignant phenotype of glioblastoma by mediating immune escape and invasiveness. Clin Cancer Res (2011) 1.03
Notch1 signaling promotes survival of glioblastoma cells via EGFR-mediated induction of anti-apoptotic Mcl-1. Oncogene (2012) 1.03
Human astrocytic brain tumors express AP02L/TRAIL. Acta Neuropathol (1999) 0.99
Epigenetic silencing of death receptor 4 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in gliomas. Clin Cancer Res (2009) 0.98
Modulation of Mcl-1 sensitizes glioblastoma to TRAIL-induced apoptosis. Apoptosis (2014) 0.95
alpha-Tocopheryl succinate and derivatives mediate the transcriptional repression of androgen receptor in prostate cancer cells by targeting the PP2A-JNK-Sp1-signaling axis. Carcinogenesis (2009) 0.93
Interferon-alpha-induced expression of phospholipid scramblase 1 through STAT1 requires the sequential activation of protein kinase Cdelta and JNK. J Biol Chem (2005) 0.92
TRAIL conjugated to nanoparticles exhibits increased anti-tumor activities in glioma cells and glioma stem cells in vitro and in vivo. Neuro Oncol (2012) 0.88
Role of the phosphatase PP4 in the activation of JNK-1 in prostate carcinoma cell lines PC-3 and LNCaP resulting in increased AP-1 and EGR-1 activity. Biol Res (2005) 0.88
BNIP3 acts as transcriptional repressor of death receptor-5 expression and prevents TRAIL-induced cell death in gliomas. Cell Death Dis (2013) 0.85
Predominant antitumor effects by fully human anti-TRAIL-receptor 2 (DR5) monoclonal antibodies in human glioma cells in vitro and in vivo. Neuro Oncol (2010) 0.85
Notch inhibition restores TRAIL-mediated apoptosis via AP1-dependent upregulation of DR4 and DR5 TRAIL receptors in MDA-MB-231 breast cancer cells. Int J Oncol (2013) 0.85
2-Tellurium-bridged β-cyclodextrin, a thioredoxin reductase inhibitor, sensitizes human breast cancer cells to TRAIL-induced apoptosis through DR5 induction and NF-κB suppression. Carcinogenesis (2010) 0.84
Efficacy of adenovirally expressed soluble TRAIL in human glioma organotypic slice culture and glioma xenografts. Cell Death Dis (2011) 0.84
Retinoic acid receptor beta silences human papillomavirus-18 oncogene expression by induction of de novo methylation and heterochromatinization of the viral control region. J Biol Chem (2007) 0.84
The role of TRAIL death receptors in the treatment of hematological malignancies. Leuk Lymphoma (2008) 0.83
Prostacyclin receptor induces STAT1 and STAT3 phosphorylations in human erythroleukemia cells: a mechanism requiring PTX-insensitive G proteins, ERK and JNK. Cell Signal (2005) 0.83
APO2L/TRAIL expression in human brain tumors. Acta Neuropathol (2000) 0.83
Hypoxia and adrenergic function: molecular mechanisms related to Egr-1 and Sp1 activation. Brain Res (2010) 0.82
beta-Ionone enhances TRAIL-induced apoptosis in hepatocellular carcinoma cells through Sp1-dependent upregulation of DR5 and downregulation of NF-kappaB activity. Mol Cancer Ther (2010) 0.80
Sp1 is involved in 8-chloro-adenosine-upregulated death receptor 5 expression in human hepatoma cells. Oncol Rep (2008) 0.80
Novel insights into the synergistic interaction of a thioredoxin reductase inhibitor and TRAIL: the activation of the ASK1-ERK-Sp1 pathway. PLoS One (2013) 0.80
Transformation, translation and TRAIL: an unexpected intersection. Cytokine Growth Factor Rev (2008) 0.78